MISSION

This Group focuses on expanding what we know about the genetic, epigenetic and immunologic backgrounds of gastrointestinal tumour diseases. Clinical trials focus on preclinical to clinical interaction and integrating early drug development, ensuring that new aspects of tumour biology are investigated with appropriate technology.

PRACTICE CHANGING RESEARCH

  • Radiation Oncology Group

    EORTC 22953 – Shortened irradiation scheme, continuous 5FU and fractionation of Mitomycin C in locally advanced anal carcinoma.

    Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Gastrointestinal Tract Cancer Cooperative Group.

    EORTC found that in patients with locally advanced anal cancer, reducing gaps between radiotherapy sequences, delivering chemotherapy during the course of radiotherapy, and reducing irradiation, improved local control the cancer and overall survival of patients, while sparing them colostomy. This new treatment scheme has been considered the new standard of treatment for this type of cancer.

    READ MORE

  • Gastro-Intestinal Group

    EORTC 40004 – CLOCC trial (Chemotherapy + Local ablation versus Chemotherapy). Randomized phase II study investigating the role of local treatment of liver metastases by radiofrequency combined with chemotherapy and of chemotherapy alone in patients with unresectable colorectal liver metastases.

    EORTC found that aggressive local treatment (which includes radiofrequency ablation +/ – resection) can prolong overall survival (OS) in patients with unresectable colorectal liver metastases.

    READ MORE

  • Gastro-Intestinal Group

    EORTC 40953 – Randomized phase II study of weekly 24 h infusion of high dose 5-FU plus or minus Folinic Acid (HD-FU/FA) versus HD-FU/FA plus biweekly Cisplatin in advanced gastric cancer.

    EORTC established the efficacy of the combined treatment of 5FU with cisplatin, in patients with advanced gastric cancer. This further contributed to the wealth of knowledge for treating advanced gastric cancer.

    READ MORE

  • Gastro-Intestinal Group

    EORTC 40983 – Pre-and Post-Operative Chemotherapy with Oxaliplatin 5FU/LV versus Surgery alone in Resectable Liver Metastases from Colorectal Origin- Phase III Study

    EORTC found that in patients with resectable liver metastases from colorectal cancer, the perioperative chemotherapy with FOLFOX4, resulted in progression free survival. The study set a new international standard of care in patients who are candidates for removal of liver metastases caused by colorectal cancer (CRC).

    READ MORE

  • Gastro-Intestinal Group

    EORTC 40993 – International phase III open label randomized trial comparing CPT-11 in combination with high dose 5FU/Folinic acid infusional regimen (group A) to the same high dose 5FU/Folinic acid infusional regimen (group B) alone as adjuvant treatment stage III colon cancer (PETACC-3).

    This EORTC study results showed the absence of benefit in adding irinotecan to 5FU treatment, in the adjuvant setting of stage III colon cancer.

    READ MORE

  • Gastro-Intestinal Group

    EORTC 1409 – A prospective Colorectal Liver Metastasis Database with an Integrated Quality Assurance program

    Surgery has a definite role in offering cure to cancer patients, nonetheless there is a also a need to improve surgical research. Responding to this need, EORTC embarked on a collaborative project with ESSO to achieve excellent surgical research and care for cancer patients. It aims to map out challenges and initiate a sustainable collaboration to advance cancer surgery research in Europe. The pilot project under this collaboration looks at patients with colorectal liver metastasis.

    READ MORE

  • Jan-03
  • Jan-07
  • Jun-07
  • Mar-08
  • Jul-09
  • May-19

LATEST PUBLICATIONS

Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up